Trend Press Wire

Antisense and RNAi Therapeutics Market Size, Share- Industry Research 2018 to 2026

Press release   •   Aug 29, 2019 06:25 EDT

The global Antisense and RNAi Therapeutics Market is expected to reach US$1.9 billion by 2026 growing at a CAGR of 7.3% during the forecast period 2018 to 2026.

Market Overview:

Antisense and RNAi Therapeutics Market 2018 - 2026 research report includes the SWOT analysis that's Strengths, Weakness, Opportunities and Threats which provides you complete analysis of competitors, market growth, market share and in addition as CAGR comparison by region. The report provides analysis of the global Antisense and RNAi Therapeutics Market for the period from 2016 to 2026, wherein 2018–2026 is the forecast period and 2018 is the base year. Data for 2017 has been included as historical information.

The report covers all trends and technologies expected to play a major role in growth of the global Antisense and RNAi Therapeutics Market during the forecast period. It highlights drivers, restraints, and opportunities expected to influence the market from 2018 to 2026. The study provides a holistic perspective on the Antisense and RNAi Therapeutics Market, in terms of revenue (in US$ Mn) and volume (in million units), across different regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South America. The report highlights key trends affecting the Antisense and RNAi Therapeutics Market at the global level. Prominent countries/sub-regions covered in the report include the U.S., Canada, Germany, France, the U.K., Italy, Russia, India, China, Japan, South Korea, South East Asia, GCC, South Africa, and Brazil.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1062

The report comprises detailed ecosystem analysis, which provides a comprehensive view of the global Antisense and RNAi Therapeutics Market. Porter’s five forces model has also been included to help understand the competition landscape of the market. Additionally, current indicators of diverse macro-economic factors are contextualized under key market indicators.

The report also analyzes the Antisense and RNAi Therapeutics Market on the basis of various segments. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Scope of the Antisense and RNAi Therapeutics Market Report:

The study provides a decisive view of the Antisense and RNAi Therapeutics Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Segmentation:

Market By Technology

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

Market By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Other

Market By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

North America is a key market, with U.S. mirroring various RNAi therapeutics at present in formative pipelines. Various biotechnology organizations have made significantly high interests in RNAi restorative advancement. Enormous pharmaceutical engineers have gone into cooperation understandings or permitting manages various littler firms trying to gain by the normal revenue development of this market. AstraZeneca's concurrence with Ionis Pharmaceuticals is one of the striking arrangements that mirror the pattern of developing interests in antisense innovation.

Market Participants / Key Players:

Few of the main businesses present in the global Antisense & RNAi therapeutics market are Benitec Biopharma, GSK, Alnylam Pharmaceuticals, Sanofi-Genzyme, and Marina Biosciences. Substantial strategic initiatives undertaken by global businesses include new product launch, partnerships, and acquisitions.And also, growing R&D investments paired with technical advancements to commercialize highly efficient products are expected to offer huge growth opportunities for industry participants.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Research Methodology

Secondary research sources that are typically referred to include, but are not limited to company websites, annual reports, financial reports, broker reports, investor presentations, SEC filings, internal and external proprietary databases, relevant patent and regulatory databases, national government documents, statistical databases, market reports, news articles, press releases, webcasts specific to companies operating in the market, national government documents, statistical databases, and Factiva.

Primary research involves e-mail interactions, telephonic interviews, and face-to-face interviews conducted for each market segment across geographies. ARC conducts primary interviews on an ongoing basis with market participants and commentators in order to validate the data and analysis. Primary interviews provide firsthand information on market size, market trends, growth trends, competition landscape, and market outlook. These help validate and strengthen secondary research findings. They also help develop the analysis team’s expertise and market understanding.

VIEW FULL RESEARCH REPORT@ https://www.acumenresearchandconsulting.com/antisense-and-rnai-therapeutics-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Antisense & RNAi Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antisense & RNAi Therapeutics Market By Technology
1.2.2.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Antisense & RNAi Therapeutics Market Revenue Share By Technology in 2017
1.2.2.3. RNA Interference
1.2.2.4. Antisense RNA
1.2.2.5. Others
1.2.3. Antisense & RNAi Therapeutics Market By Application
1.2.3.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Oncology
1.2.3.3. Cardiovascular
1.2.3.4. Respiratory Disorders
1.2.3.5. Renal Diseases
1.2.3.6. Neurodegenerative Disorders
1.2.3.7. Genetic Disorders
1.2.3.8. Infectious Diseases
1.2.3.9. Others
1.2.4. Antisense & RNAi Therapeutics Market By Route of Administration
1.2.4.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.4.2. Pulmonary Delivery
1.2.4.3. Intravenous Injections
1.2.4.4. Intradermal Injections
1.2.4.5. Intraperitoneal Injections
1.2.4.6. Topical Delivery
1.2.4.7. Other Delivery Methods
1.2.5. Antisense & RNAi Therapeutics Market by Geography
1.2.5.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017

CHAPTER 4. ANTISENSE & RNAI THERAPEUTICS MARKET BY TECHNOLOGY

4.1. Global Antisense & RNAi Therapeutics Revenue By Technology
4.2. RNA Interference
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Antisense RNA
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTISENSE & RNAI THERAPEUTICS MARKET BY APPLICATION

5.1. Global Antisense & RNAi Therapeutics Revenue By Application
5.2. Oncology
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Cardiovascular
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Respiratory Disorders
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Renal Diseases
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Neurodegenerative Disorders
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Genetic Disorders
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Infectious Diseases
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Others
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTISENSE & RNAI THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION

6.1. Global Antisense & RNAi Therapeutics Revenue By Route of Administration
6.2. Pulmonary Delivery
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Intravenous Injections
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Intradermal Injections
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Intraperitoneal Injections
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Topical Delivery
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Other Delivery Methods
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

7.1. North America Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antisense & RNAi Therapeutics Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

8.1. Europe Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

9.1. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

10.1. Latin America Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

11.1. Middle East Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY

12.1. Africa Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Benitec Biopharma
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. GSK
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Alnylam Pharmaceuticals
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Sanofi-Genzyme
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Marina Biosciences
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1062

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.